Live Well
Back to Live Well
Lowest Net Cost Formulary Update Bulletin
The changes in this update apply to all groups that use OptumRx
The majority of these changes include decisions that occurred as a result of our May 2025 Pharmacy and Therapeutics Committee (P&T) meeting. Members negatively impacted by one of these changes will be sent a letter this month.
FORMULARY UPDATES
Additions
These drugs will be added to the formulary effective Oct. 1, 2025.
| Product | Drug Class/Category | Utilization Management Programs | Formulary Status |
|---|---|---|---|
| Alhemo | Hemophilia | --- | Non-Preferred Specialty |
| Alyftrek | Cystic Fibrosis | PA/QL | Non-Preferred Specialty |
| Bizengri | Cancer | PA | Non-Preferred Specialty |
| Datroway | Cancer | PA | Non-Preferred Specialty |
| Hympavzi | Hemophilia | --- | Non-Preferred Specialty |
| Itovebi | Cancer | PA/QL | Non-Preferred Specialty |
| Revuforj | Cancer | PA/QL | Non-Preferred Specialty |
| Tryngolza | Familial Chylomicronemia Syndrome (FCS) | PA/QL | Non-Preferred Specialty |
| Vyloy | Cancer | PA | Non-Preferred Specialty |
| Ziihera | Cancer | PA | Non-Preferred Specialty |
Moving to Nonformulary Status
These drugs will move to nonformulary status effective Oct. 1, 2025.
• Allopurinol tab 200mg
• Arava 10mg
• Estrace tab 1mg
• Estrace tab 2mg
• Loestrin FE tab 1.5/30
• Mesnex tab 400mg
• Solu-Cortef inj 100mg
Medical Benefit Only
The following specialty drugs will be eligible for coverage under the medical benefit effective Oct. 1, 2025.
• Aucatzyl
• Kebilidi
• Ryoncil